DOAC Dataform Updated 08/20/2024
Submitted by admin on Thu, 2024-08-22 17:23The data form document has been updated. We have added specific questions regarding hematuria adverse events in the follow-up form. Download it here.
The data form document has been updated. We have added specific questions regarding hematuria adverse events in the follow-up form. Download it here.
The document was revised, for dabigatran (all Indications) and rivaroxaban (all Indications except CAD & PAD) to add the following statement: “Consider alternative anticoagulation in patients who develop significant acute renal failure”
Page 3 of the document has been revised, for all DOACs, with the following “Not recommended as first-line therapy in patients with antiphospholipid antibody syndrome (APS)”.
DOSE protocol document was revised on 01/08/2024 - includes minor typo corrections.
DOSE protocol document was revised on 11/01/2023 - a reintroduction of posaconazole to the DOSE alerts.
DOSE protocol document was revised on 7/25/2023 - an update regarding use of Rivaroxaban.
The data dictionary has been updated. The form has been revised to clarify Section 5 Medications. Download it here.
DOSE protocol document was revised on 4/19/2023.
Data Dictionary and DOSE Protocol updates have been posted. These are for introducing cobicistat and tucatinib, and updating the DOSE Alerts to handle these meds.